Advancing Multiple Sclerosis
1 clinical trials · Condition
◉ Watch Advancing Multiple Sclerosis
| Record | Firm | Date |
|---|---|---|
| Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients (NCT03623243) | Novartis Pharmaceuticals | 2019-02-14 |
Track Advancing Multiple Sclerosis automatically
Every clearance here is in the API, with alerts when new ones post.